Reported 2 days ago
Eli Lilly and Company (NYSE:LLY) is gaining positive attention from analysts, as Leerink Partners and Jefferies both reaffirmed their 'Buy' ratings. The company’s growth potential, particularly due to advancements in GLP-1 receptor agonists, positions it favorably in the market for diabetes treatments and neurology. The recent findings linking GLP-1RAs to improved health outcomes have fueled optimism for the company's future growth, with Jefferies estimating a price target of $1,057 while the stock trades currently at $805.43.
Source: YAHOO